MARKET

DTIL

DTIL

Precision Biosciences
NASDAQ
7.41
-0.02
-0.27%
Opening 12:52 08/17 EDT
OPEN
7.45
PREV CLOSE
7.43
HIGH
7.54
LOW
7.39
VOLUME
106.99K
TURNOVER
--
52 WEEK HIGH
9.62
52 WEEK LOW
3.530
MARKET CAP
204.53M
P/E (TTM)
-2.6458
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DTIL last week (0810-0814)?
Weekly Report · 7h ago
Precision BioSciences: Buy Rating Reiterated as ARCUS HBV and DMD Catalysts De-Risk Platform; $60 Price Target Maintained
TipRanks · 5d ago
Weekly Report: what happened at DTIL last week (0803-0807)?
Weekly Report · 08/10 09:48
*Precision Biosciences 2Q Loss $32.7M >DTIL
Dow Jones · 08/06 11:01
Press Release: Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Dow Jones · 08/06 11:01
Press Release: Precision BioSciences Reports -2-
Dow Jones · 08/06 11:01
*Precision Biosciences 2Q Loss/Shr $1.26 >DTIL
Dow Jones · 08/06 11:01
Press Release: Precision BioSciences Reports -3-
Dow Jones · 08/06 11:01
More
About DTIL
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.

Webull offers Precision BioSciences Inc stock information, including NASDAQ: DTIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DTIL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DTIL stock methods without spending real money on the virtual paper trading platform.